{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:24:05Z","timestamp":1791480245293,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jocn.2023.09.026","type":"journal-article","created":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T07:05:28Z","timestamp":1696489528000},"page":"136-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Dalfampridine as a promising agent in the management of hereditary spastic paraplegia: A triple-blinded, randomized, placebo-controlled pilot trial"],"prefix":"10.1016","volume":"117","author":[{"given":"Ferda","family":"Selcuk Muhtaroglu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beliz","family":"Belgen Kaygisiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sila","family":"Usar Incirli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turhan","family":"Kahraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2023.09.026_b0005","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.3390\/ijms23147665","article-title":"The Puzzle of Hereditary Spastic Paraplegia: From Epidemiology to Treatment","volume":"23","author":"Meyyazhagan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jocn.2023.09.026_b0010","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/S1474-4422(19)30235-2","article-title":"Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches","volume":"18","author":"Shribman","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jocn.2023.09.026_b0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12311-016-0803-z","article-title":"Hereditary Spastic Paraplegia: Clinical and Genetic Hallmarks","volume":"16","author":"de Souza","year":"2017","journal-title":"Cerebellum"},{"key":"10.1016\/j.jocn.2023.09.026_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104430","article-title":"Hereditary spastic paraparesis: The real-world experience from a Neurogenetics outpatient clinic","volume":"65","author":"Cunha","year":"2022","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jocn.2023.09.026_b0025","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.expneurol.2014.06.011","article-title":"Hereditary spastic paraplegia: Clinical-genetic characteristics and evolving molecular mechanisms","volume":"261","author":"Lo Giudice","year":"2014","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jocn.2023.09.026_b0030","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fneur.2019.00003","article-title":"Management of hereditary spastic paraplegia: a systematic review of the literature","volume":"10","author":"Bellofatto","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.jocn.2023.09.026_b0035","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clineuro.2014.05.024","article-title":"Intrathecal baclofen therapy for the symptomatic treatment of hereditary spastic paraplegia","volume":"123","author":"Margetis","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jocn.2023.09.026_b0040","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.apmr.2015.01.012","article-title":"Improved gait performance in a patient with hereditary spastic paraplegia after a continuous intrathecal baclofen test infusion and subsequent pump implantation: a case report","volume":"96","author":"Heetla","year":"2015","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.jocn.2023.09.026_b0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/00002060-199807000-00021","article-title":"Therapeutic electrical stimulation for spasticity: quantitative gait analysis","volume":"77","author":"Pease","year":"1998","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.jocn.2023.09.026_b0050","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pmrj.2014.09.008","article-title":"Robot-assisted gait training in a patient with hereditary spastic paraplegia","volume":"7","author":"Seo","year":"2015","journal-title":"PM R"},{"key":"10.1016\/j.jocn.2023.09.026_b0055","first-page":"110","article-title":"Physical therapy interventions for the patients with hereditary spastic paraparesis. An exploratory case reports","volume":"3","author":"Samuel","year":"2013","journal-title":"Int J Physioth Res"},{"key":"10.1016\/j.jocn.2023.09.026_b0060","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.gaitpost.2014.01.010","article-title":"The effect of hydrotherapy treatment on gait characteristics of hereditary spastic paraparesis patients","volume":"39","author":"Zhang","year":"2014","journal-title":"Gait Posture"},{"key":"10.1016\/j.jocn.2023.09.026_b0065","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/mds.28523","article-title":"Randomized Trial of Botulinum Toxin Type A in Hereditary Spastic Paraplegia - The SPASTOX Trial","volume":"36","author":"Diniz de Lima","year":"2021","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2023.09.026_b0070","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1093\/brain\/awx273","article-title":"Hereditary spastic paraplegia type 5: natural history, biomarkers and a randomized controlled trial","volume":"140","author":"Sch\u00f6ls","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.jocn.2023.09.026_b0075","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","article-title":"Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment","volume":"111","author":"Judge","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jocn.2023.09.026_b0080","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0361-9230(89)90126-3","article-title":"Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury","volume":"22","author":"Blight","year":"1989","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jocn.2023.09.026_b0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/ana.22240","article-title":"A phase 3 trial of extended release oral dalfampridine in multiple sclerosis","volume":"68","author":"Goodman","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jocn.2023.09.026_b0090","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00415-015-7707-6","article-title":"Dalfampridine in hereditary spastic paraplegia: a prospective, open study","volume":"262","author":"B\u00e9reau","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2023.09.026_b0095","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000449375","article-title":"The Effects of Dalfampridine on Hereditary Spastic Paraparesis","volume":"76","author":"Uygunoglu","year":"2016","journal-title":"Eur Neurol"},{"issue":"suppl 2","key":"10.1016\/j.jocn.2023.09.026_b0100","article-title":"Symptomatic treatment of hereditary spastic paraplegias with fampridine: a pilot study [abstract]","volume":"34","author":"Ros\u00e1rio","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.jocn.2023.09.026_b0105","doi-asserted-by":"crossref","unstructured":"Meyyazhagan A, Orlacchio A. Hereditary Spastic Paraplegia: An Update. Int J Mol Sci. 2022;23.","DOI":"10.3390\/ijms23031697"},{"key":"10.1016\/j.jocn.2023.09.026_b0110","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1185\/03007995.2011.639752","article-title":"Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis","volume":"28","author":"Coleman","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jocn.2023.09.026_b0115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jocn.2023.09.026_b0120","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/02701367.1999.10608028","article-title":"A 30-s chair-stand test as a measure of lower body strength in community-residing older adults","volume":"70","author":"Jones","year":"1999","journal-title":"Res Q Exerc Sport"},{"key":"10.1016\/j.jocn.2023.09.026_b0125","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ptsp.2006.11.004","article-title":"Establishing normal values for lower extremity muscle length in college-age students","volume":"8","author":"Corkery","year":"2007","journal-title":"Phys Ther Sport"},{"key":"10.1016\/j.jocn.2023.09.026_b0130","doi-asserted-by":"crossref","first-page":"576","DOI":"10.23736\/S1973-9087.17.04796-7","article-title":"Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis","volume":"54","author":"Meseguer-Henarejos","year":"2018","journal-title":"Eur J Phys Rehabil Med"},{"key":"10.1016\/j.jocn.2023.09.026_b0135","first-page":"10","article-title":"Using the Student's t-test with extremely small sample sizes","volume":"18","author":"De Winter","year":"2013","journal-title":"Pract Assess Res Eval"},{"key":"10.1016\/j.jocn.2023.09.026_b0140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13023-021-01694-8","article-title":"Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials","volume":"16","author":"Zhang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jocn.2023.09.026_b0145","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ptj\/80.9.896","article-title":"Predicting the Probability for Falls in Community-Dwelling Older Adults Using the Timed Up & Go Test","volume":"80","author":"Shumway-Cook","year":"2000","journal-title":"Phys Ther"},{"key":"10.1016\/j.jocn.2023.09.026_b0150","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1212\/01.wnl.0000228242.53336.90","article-title":"The Spastic Paraplegia Rating Scale (SPRS)","volume":"67","author":"Sch\u00fcle","year":"2006","journal-title":"Neurology"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586823002886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:35:19Z","timestamp":1760823319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586823002886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":30,"alternative-id":["S0967586823002886"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2023.09.026","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dalfampridine as a promising agent in the management of hereditary spastic paraplegia: A triple-blinded, randomized, placebo-controlled pilot trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2023.09.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}